Alaunos Therapeutics Files Q1 2025 10-Q
Ticker: TCRT · Form: 10-Q · Filed: May 15, 2025 · CIK: 1107421
| Field | Detail |
|---|---|
| Company | Alaunos Therapeutics, INC. (TCRT) |
| Form Type | 10-Q |
| Filed Date | May 15, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, pharmaceuticals, financial-reporting
TL;DR
**Alaunos Therapeutics Q1 2025 10-Q filed. Financials and operations update.**
AI Summary
Alaunos Therapeutics, Inc. filed a 10-Q for the period ending March 31, 2025. The filing details financial information and business operations. Key dates and agreements mentioned include the MD Anderson License and Research and Development Agreements dating back to 2004 and 2015/2019 respectively. The company's former names include Ziopharm Oncology Inc. and Easyweb Inc.
Why It Matters
This filing provides investors with the latest financial performance and operational updates for Alaunos Therapeutics, Inc. as of March 31, 2025.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Alaunos Therapeutics faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20250331 — Reporting Period End Date (Indicates the end of the fiscal quarter for which financial data is reported.)
- 20250515 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Alaunos Therapeutics, Inc. (company) — Filer of the 10-Q
- March 31, 2025 (date) — End of reporting period
- 2004-08-24 (date) — Date of MD Anderson License agreement
- 2015 and 2019 (date) — Dates of Research and Development Agreements
- Ziopharm Oncology Inc. (company) — Former company name
- Easyweb Inc. (company) — Former company name
- The University of Texas MD Anderson Cancer Center (company) — Partner in license agreement
- The Texas A&M University System (company) — Partner in license agreement
FAQ
What is the primary business of Alaunos Therapeutics, Inc. as indicated by its SIC code?
Alaunos Therapeutics, Inc. is classified under Pharmaceutical Preparations [2834], indicating its primary business is in the development and manufacturing of pharmaceutical products.
When did Alaunos Therapeutics, Inc. change its name from Ziopharm Oncology Inc.?
The filing indicates a name change from Ziopharm Oncology Inc. occurred on September 19, 2005.
What are the key agreements mentioned in the filing and their associated dates?
The filing mentions the MD Anderson License and the Two Thousand Fifteen and Two Thousand Nineteen Research and Development Agreement, with the license dating back to August 24, 2004, and the R&D agreements from 2015 and 2019.
What is the fiscal year end for Alaunos Therapeutics, Inc.?
The fiscal year end for Alaunos Therapeutics, Inc. is December 31.
What is the business address and phone number provided for Alaunos Therapeutics, Inc.?
The business address is 2617 Bissonnet St, Suite 233, Houston, TX 77005, and the business phone number is (346) 355-4099.
Filing Details
This Form 10-Q (Form 10-Q) was filed with the SEC on May 15, 2025 regarding Alaunos Therapeutics, Inc. (TCRT).